Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the relative effectiveness of risperidone Consta injections
occurring every 2 weeks in contrast to treatment as usual in preventing symptomatic relapse
and rates of rehospitalization or admission into respite care for bipolar patients.
Hypothesis: Risperdal Consta injections every 2 weeks will reduce the number of symptomatic
relapses into mania, hypomania, mixed state, or depression, as shown by key indicators that
include symptomatic relapse, rehospitalizations, emergency or urgent care visits, respite
care, and intensive outpatient treatment as compared to treatment as usual.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center